green
Positive treatment
Quoted verbatim 1×
3.4 score
“rule 24(a)(2) was not designed to provide a forum for witnesses in the underlying action to protect their reputation in the community.”
Treatment trajectory · 1987 → 2026 · click a year to view as-of
1987
2006
2026
Top citers, strongest first. 3 distinct citers.
How cited ↗
discussed
Cited as authority (quoted)
Osmer v. BP Exploration & Production, Inc.
rule 24(a)(2) was not designed to provide a forum for witnesses in the underlying action to protect their reputation in the community.
cited
Cited "see"
Allison v. Merck and Co., Inc.
See Walker v. Merck and Company, 648 F.Supp. 931 (M.D.Ga.1986), aff'd, 831 F.2d 1069 (11th Cir.1987); Boruski v. United States, 803 F.2d 1421 (7th Cir.1986).
discussed
Cited "see, e.g."
Mazur v. Merck & Co., Inc.
Incollingo, 282 A.2d at 220 (learned intermediary is the prescribing physician); see also Walker v. Merck & Co., Inc., 648 F.Supp. 931 (M.D.Ga.1986), affd without op., 831 F.2d 1069 (11th Cir.1987) (school nurse qualifies as a learned intermediary).
Retrieving the full opinion text from the archive…
Caulder
v.
Bowen
v.
Bowen
87-3187.
Court of Appeals for the Eleventh Circuit.
Oct 1, 1987.
831 F.2d 1069
Published
Citer courts: E.D. Louisiana (1)
Caulder
v.
Bowen[*]
NO. 87-3187
United States Court of Appeals,
Eleventh Circuit.
OCT 01, 1987
Appeal From: M.D.Fla.
VACATED AND REMANDED.
*
Fed.R.App.P. 34(a); 11th Cir.R. 23